ClinicalTrials.gg
RecruitingNCT06374589CLOUDHFOTUpdated Jan 28, 2025

Closed-Loop O2 Use During High Flow Oxygen Treatment of Critical Care Adult Patients (CLOUDHFOT)

An interventional study of Closed-loop FiO2 controller and Conventional in Acute Hypoxemic Respiratory Failure, Acute Hypercapnic Respiratory Failure and Respiratory Depression, sponsored by Başakşehir Çam & Sakura City Hospital. Recruiting at 2 sites in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by Başakşehir Çam & Sakura City Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Respiratory Insufficiency with a site in Turkey — 10 open to participants now, 10 under way, none of them phase 3. Respiratory Insufficiency · Turkey.

Planned enrollment
19th of 26
50 · median 90
Started
2024
with 7 others
No phase
24 of 51
4 open now
Registered
33rd of 51
by date

Among the 51 studies in Respiratory Insufficiency with a site in Turkey, this one is the 19th largest by planned enrollment of the 26 interventional ones that give a count, is one of 8 that started in 2024, is one of 24 with no phase, and was the 33rd registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

10 of the 51 studies in Respiratory Insufficiency with a site in Turkey are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Respiratory Insufficiency with a site in Turkey, or all of them as a file.
02

Study summary

High flow nasal oxygen therapy (HFNO) is an established modality in the supportive treatment of patients suffering from acute hypoxemic respiratory failure. The high humidified gas flow supports patient's work of breathing, reduces dead space ventilation, and improves functional residual capacity while using an unobtrusive patient's face interface [Mauri et al, 2017; Möller et al, 2017].

As hyperoxia is considered not desirable [Barbateskovic et al, 2019] during any oxygen therapy, the inspired O2 concentration is usually adapted to a pre-set SpO2 target-range of 92-96% in patients without hypercapnia risk, and of 88-92% if a risk of hypercapnia is present [O'Driscoll et al, 2017; Beasley et al, 2015]. In most institutions, the standard of care is to manually adapt the FiO2, although patients frequently have a SpO2 value outside the target range.

A new closed loop oxygen controller designed for HFNO was recently developed (Hamilton Medical, Bonaduz, Switzerland). The clinician sets SpO2 targets, and the software option adjusts FiO2 to keep SpO2 within the target ranges. The software option offers some alarms on low and high SpO2 and high FiO2. Given the capability, on the one hand, to quickly increase FiO2 in patients developing sudden and profound hypoxia, and, on the other hand, of automatically preventing hyperoxia in patients improving their oxygenation, such a system could be particularly useful in patients treated with HFNO.

A short-term (4 hours vs 4 hours) crossover study indicated that this technique improves the time spent within SpO2 pre-defined target for ICU patients receiving high-flow nasal oxygen therapy [Roca et al, 2022]. Due to its simplicity, HFNO is increasingly used outside the ICU during transport and in the Emergency Room (ER). This environment poses specific challenges, as patients may deteriorate very quickly and depending on patient's flow, healthcare providers can easily be overwhelmed. We thus propose to evaluate closed loop controlled HFNO in ER patients.

The hypothesis of the study is that closed loop oxygen control increases the time spent within clinically targeted SpO2 ranges and decreases the time spent outside clinical target SpO2 ranges as compared to manual oxygen control in ER patients treated with HFNO.

03

Conditions studied

  • Acute Hypoxemic Respiratory Failure
  • Acute Hypercapnic Respiratory Failure
  • Respiratory Depression
  • Respiratory Failure

Keywords

  • Acute respiratory failure (ARF)
  • HFNC
  • Closed-loop
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient admitted to the ER
  • Requiring NHFO
  • Requiring FiO2 ≥ 30% to keep SpO2 in the target ranges defined by the clinician
  • Aged over 18 years
  • Written signed and dated by the patient or one relative in case that the patient is unable to consent, after full explanation of the study by the investigator and prior to study participation
  • In case that the consent is given by the relative, patient consent will be requested as soon as the patient will be able to provide informed written consent

Exclusion criteria

Exclusion Criteria:

Patients who fulfil any of the following exclusion criteria are not eligible for study participation:

  • Patient with indication for immediate CPAP, NIV, or invasive mechanical ventilation
  • Hemodynamic instability defined as a need of continuous infusion of epinephrine or norepinephrine > 1 mg/h
  • Low quality on the SpO2 measurement using finger and ear sensor (quality index below 60% on the Massimo SpO2 sensor, which is displayed by a red or orange color bar)
  • Severe acidosis (pH ≤ 7.30)
  • Pregnant woman
  • Patients deemed at high risk for need of mechanical ventilation within the next 12 hours
  • Chronic or acute dyshemoglobinemia: methemoglobin, CO poisoning, sickle cell disease
  • Tracheotomized patient
  • Formalized ethical decision to withhold or withdraw life support
  • Patient under guardianship
  • Patient deprived of liberties
  • Patient included in another interventional research study under consent
  • Patient already enrolled in the present study in a previous episode of acute respiratory failure

Post enrollment exclusion criteria

  • Apparition of a persistent low quality SpO2 signal
  • Need for an emergent intubation
  • Discharge from ER
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Close-loop FiO2 Controller

    Six hours period where the fraction of inspired oxygen (FiO2) delivered will be automatically titrated based on SpO2 values obtained from the patient.

    Device: Closed-loop FiO2 controller

  • Active comparator
    Conventional

    Six hours period where the fraction of inspired oxygen (FiO2) delivered will be manually titrated by clinician based on SpO2 values obtained from the patient.

    Device: Conventional

Interventions

  • DeviceClosed-loop FiO2 controller

    Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.

  • DeviceConventional

    Six hours period where the fraction of inspired oxygen (FiO2) delivered will be manually titrated by clinician based on SpO2 values obtained from the patient.

06

What researchers measure

Primary outcomes

  1. Percentage of time spent in optimal SpO2 range

    The optimal SpO2 range will be defined according to the SpO2 targets determined by the clinician.

    Time frame: 6 hours

Secondary outcomes

  1. Percentage of time with SpO2 signal available

    Time with SpO2 signal available

    Time frame: 6 hours

  2. Percentage of time with SpO2 below target range

    SpO2 values below the optimal range

    Time frame: 6 hours

  3. Percentage of time with SpO2 above target range

    SpO2 values above the optimal range

    Time frame: 6 hours

  4. Percentage of time with SpO2 outside optimal range

    SpO2 values outside the optimal range

    Time frame: 6 hours

  5. Percentage of time with with FiO2 below 40%

    Duration of time with FiO2 \< 40 %

    Time frame: 6 hours

  6. Percentage of time with with FiO2 above 60%

    Duration of time with FiO2 \> 60 %

    Time frame: 6 hours

  7. Percentage of time with with FiO2 = 100%

    Duration of time with FiO2 = 60 %

    Time frame: 6 hours

  8. Mean SpO2/FiO2

    Mean SpO2/FiO2

    Time frame: 6 hours

  9. Number of events with SpO2 below of target range (duration >10 s)

    Frequency of events with SpO2 below of target range (duration \>10 s)

    Time frame: 6 hours

  10. Number of events with SpO2 below of target range (duration >60 s)

    Frequency of events with SpO2 below of target range (duration \>60 s)

    Time frame: 6 hours

  11. Number of events with SpO2 below the predefined low SpO2 emergency limit

    Frequency of events with SpO2 below of the predefined low SpO2 emergency limit

    Time frame: 6 hours

  12. Number of events with SpO2 above the predefined low SpO2 emergency limit

    Frequency of events with SpO2 above of the predefined low SpO2 emergency limit

    Time frame: 6 hours

  13. Total oxygen use

    Amount of additional oxygen use

    Time frame: 6 hours

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Sandal O, Ceylan G, Topal S, Hepduman P, Colak M, Novotni D, Soydan E, Karaarslan U, Atakul G, Schultz MJ, Agin H. Closed-loop oxygen control improves oxygenation in pediatric patients under high-flow nasal oxygen-A randomized crossover study. Front Med (Lausanne). 2022 Nov 16;9:1046902. doi: 10.3389/fmed.2022.1046902. eCollection 2022. PubMed 36465920 ↗
  • Roca O, Caritg O, Santafe M, Ramos FJ, Pacheco A, Garcia-de-Acilu M, Ferrer R, Schultz MJ, Ricard JD. Closed-loop oxygen control improves oxygen therapy in acute hypoxemic respiratory failure patients under high flow nasal oxygen: a randomized cross-over study (the HILOOP study). Crit Care. 2022 Apr 14;26(1):108. doi: 10.1186/s13054-022-03970-w. PubMed 35422002 ↗
  • Dijkman KP, Goos TG, Dieleman JP, Mohns T, van Pul C, Andriessen P, Kroon AA, Reiss IK, Niemarkt HJ. Predictive Intelligent Control of Oxygenation in Preterm Infants: A Two-Center Feasibility Study. Neonatology. 2023;120(2):235-241. doi: 10.1159/000527539. Epub 2022 Dec 8. PubMed 36481622 ↗
  • O'Driscoll BR, Kirton L, Weatherall M, Bakerly ND, Turkington P, Cook J, Beasley R. Effect of a lower target oxygen saturation range on the risk of hypoxaemia and elevated NEWS2 scores at a university hospital: a retrospective study. BMJ Open Respir Res. 2024 Feb 29;11(1):e002019. doi: 10.1136/bmjresp-2023-002019. PubMed 38423953 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2025, 21 months after the start.

Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 21 months is below that.

Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2024
First posted
Apr 18, 2024
StartActual
Mar 21, 2024
Primary completionEst.
Dec 30, 2025
CompletionEst.
May 30, 2026
Last update
Jan 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06374589
Collaborators
Hamilton Medical AG
Responsible party
Sponsor
First posted
Apr 18, 2024
Start date
Mar 21, 2024
Primary completion
Dec 30, 2025 (estimated)
Completion
May 30, 2026 (estimated)
Last update
Jan 28, 2025

Study contacts

Ramazan Guven, Associate prof
Contact
drramazanguven@gmail.com
05354935995
Mustafa Colak, MD
Contact
colakk@hotmail.com.tr
Ramazan Guven, Associate prof
principal investigator · Basaksehir Cam Sakura city Hospital, Istanbul

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion